Related Experiment Video
Updated: Mar 22, 2026
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Vitamin A-aldehyde adducts: AMD risk and targeted therapeutics
1Department of Ophthalmology, Columbia University Medical Center, New York, NY 10032; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032 jrs88@cumc.columbia.edu.
Abstract:
Although currently available treatment options for age-related macular degeneration (AMD) are limited, particularly for atrophic AMD, the identification of predisposing genetic variations has informed clinical studies addressing therapeutic options such as complement inhibitors and anti-inflammatory agents. To lower risk of early AMD, recommended lifestyle interventions such as the avoidance of smoking and the intake of low glycemic antioxidant-rich diets have largely followed from the identification of nongenetic modifiable factors. On the other hand, the challenge of understanding the complex relationship between aging and cumulative damage leading to AMD has fueled investigations of the visual cycle adducts that accumulate in retinal pigment epithelial (RPE) cells and are a hallmark of aging retina. These studies have revealed properties of these compounds that provide insights into processes that may compromise RPE and could contribute to disease mechanisms in AMD. This work has also led to the design of targeted therapeutics that are currently under investigation.
Insights
Current age-related macular degeneration (AMD) treatments are limited, especially for atrophic AMD. Research into genetic factors, lifestyle changes, and retinal pigment epithelial cell damage offers new therapeutic targets for AMD.
Area of Science:
- Ophthalmology
- Genetics
- Cell Biology
Background:
- Age-related macular degeneration (AMD) presents limited treatment options, particularly for the atrophic form.
- Genetic variations and nongenetic factors like diet and smoking influence AMD risk.
- Accumulation of visual cycle adducts in retinal pigment epithelial (RPE) cells is a hallmark of retinal aging and may contribute to AMD.
Purpose of the Study:
- To explore genetic and lifestyle factors in age-related macular degeneration (AMD).
- To investigate the role of visual cycle adducts in retinal pigment epithelial (RPE) cell dysfunction and AMD pathogenesis.
- To identify potential therapeutic targets for AMD based on these findings.
Main Methods:
- Analysis of genetic variations associated with AMD.
- Evaluation of lifestyle interventions for early AMD risk reduction.
- Investigation of visual cycle adducts in RPE cells to understand aging retina processes.
Main Results:
- Identification of predisposing genetic variations guiding therapeutic strategies like complement inhibitors.
- Established lifestyle interventions (smoking avoidance, antioxidant-rich diet) for lowering early AMD risk.
- Characterization of visual cycle adducts, revealing insights into RPE compromise and AMD mechanisms.
Conclusions:
- Genetic and lifestyle factors are crucial in managing AMD.
- Understanding RPE cell damage from visual cycle adducts is key to AMD pathogenesis.
- Targeted therapeutics based on these insights are under investigation for AMD treatment.
More Related Videos
08:18Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
Published on: October 4, 2024
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...